Fingolimod -Response According to Coping - Evaluation
Fingolimod -Response According to Coping - Evaluation
This is a prospective, open-label, multi-center phase IV study to assess response to
 fingolimod initiation according to coping profile in adult patients with highly active
 relapsing remitting multiple sclerosis in France.
Inclusion Criteria:

 -  18-65 year-old male & female with RRMS (2005 revised McDonald criteria) corresponding
 to fingolimod indication (in Europe) and EDSS score 0 - 5.5 inclusive

 Exclusion Criteria:

 -  History of immune system chronic disease other than MS or known immunodeficiency
 syndrome; increased risk for opportunistic infections, including immunocompromised
 patients; severe active infections, active chronic infections; negative for
 varicella-zoster virus IgG antibodies; live or live attenuated vaccines;

 -  Active malignancies; Macular edema; Cardiac disease or medicines decreasing heart
 rate; severe liver impairment; lymphocyte count <800/mm3;

 -  Pregnant or nursing (lactating) women /child-bearing potential UNLESS they are using
 an effective contraceptive method;

 -  Hypersensitivity; participation in any clinical research study within 6 months prior
 to baseline; prior participation in a trial with fingolimod

 Other protocol-defined inclusion/exclusion criteria may apply